Schrodinger Inc
SDGR
View Detailed Chart
13.490USD
+0.550+4.25%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
993.33MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.25%
5 Days
-3.44%
1 Month
-28.21%
6 Months
-30.25%
Year to Date
-24.55%
1 Year
-47.89%
View Detailed Chart
TradingKey Stock Score of Schrodinger Inc
Currency: USD Updated: 2026-02-06Key Insights
Schrodinger Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 98 out of 482 in the Software & IT Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Schrodinger Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Schrodinger Inc Highlights
StrengthsRisks
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 207.54M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -5.62, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 70.83M shares, decreasing 9.79% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 515.00 shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
25.000
Target Price
+93.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Schrodinger Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Schrodinger Inc Info
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Its segments include Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in the material science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor), and others. Its software has been used by researchers around the world at more than 1,818 academic institutions.
Ticker SymbolSDGR
CompanySchrodinger Inc
CEOFarid (Ramy Farid)
Websitehttps://www.schrodinger.com
Related Instruments
-2.48%
-2.53%
+1.90%
-1.31%
+0.74%
-0.57%
+4.65%
+3.01%
+1.64%
+4.53%
+3.03%
+3.00%
+0.73%
-0.59%
+3.65%
+3.01%
+0.73%
+8.39%
-0.37%
+2.94%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
67758.940
-2211.190 (-3.16%)
282.580
+22.390 (+8.61%)
2012.080
-39.650 (-1.93%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
